2018
National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey
Salami JA, Warraich HJ, Valero‐Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Katzen BT, Lloyd‐Jones D, Krumholz HM, Nasir K. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. Journal Of The American Heart Association 2018, 7: e007132. PMID: 29358195, PMCID: PMC5850149, DOI: 10.1161/jaha.117.007132.Peer-Reviewed Original ResearchAdultAgedAtherosclerosisDatabases, FactualDrug CostsDrug PrescriptionsDyslipidemiasFemaleHealth Care SurveysHealth ExpendituresHealthcare DisparitiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsLongitudinal StudiesMaleMedically UninsuredMiddle AgedPractice Patterns, Physicians'Racial GroupsRetrospective StudiesRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsTreatment OutcomeUnited States
2015
Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures
Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, Ho PM, Eapen ZJ, Hernandez AF, Heidenreich PA, Bhatt DL, Peterson ED, Krumholz HM. Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. Circulation 2015, 132: 1347-1353. PMID: 26316616, PMCID: PMC4941099, DOI: 10.1161/circulationaha.115.014281.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBody Mass IndexCardiovascular AgentsComorbidityContraindicationsCross-Sectional StudiesDrug HypersensitivityDrug PrescriptionsDrug SubstitutionDrug Therapy, CombinationDrug UtilizationEvidence-Based MedicineFemaleGuideline AdherenceHeart FailureHospitalsHumansMaleMedication AdherenceMiddle AgedPatient AdmissionPatient DischargePolypharmacyPractice Guidelines as TopicQuality Assurance, Health CareConceptsHF quality measuresHydralazine/isosorbide dinitrateAngiotensin receptor blockersMedication groupHeart failureAldosterone antagonistsReceptor blockersMedication regimenIsosorbide dinitrateNew medicationsΒ-blockersEnzyme inhibitorsGuideline-directed medical therapyInitiation of angiotensinPrimary discharge diagnosisQuarter of patientsPatient's medication regimenHospital quality measuresAdequate prescribingMedication initiationHospital dischargeHospital admissionMedical therapyGuideline recommendationsDischarge diagnosis
2014
Role of Nicotinic Acid in Atherosclerosis Prevention—Reply
Jackevicius CA, Krumholz HM. Role of Nicotinic Acid in Atherosclerosis Prevention—Reply. JAMA Internal Medicine 2014, 174: 649-649. PMID: 24711201, DOI: 10.1001/jamainternmed.2013.12811.Peer-Reviewed Original ResearchImpact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada
Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE Trial on the use of ezetimibe in the United States and Canada. American Heart Journal 2014, 167: 683-689. PMID: 24766978, PMCID: PMC4215424, DOI: 10.1016/j.ahj.2014.01.014.Peer-Reviewed Original ResearchConceptsUse of ezetimibeENHANCE trialEzetimibe useProgression of atherosclerosisMain outcome measuresAtherosclerosis regression trialsMonthly numberOutcome measuresRegression trialsEzetimibeIMS HealthCommon evidence baseEvidence baseTrialsUnited StatesUtilization patternsFurther investigationDifferent utilization patternsPopulationDifferent patternsUse trendsAtherosclerosisSimvastatinProgression
2013
Use of Niacin in the United States and Canada
Jackevicius CA, Tu JV, Ko DT, de Leon N, Krumholz HM. Use of Niacin in the United States and Canada. JAMA Internal Medicine 2013, 173: 1379-1381. PMID: 23753308, DOI: 10.1001/jamainternmed.2013.6489.Peer-Reviewed Original Research
2010
Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone
Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA Warning — Geographic Variation in the Use of Rosiglitazone. New England Journal Of Medicine 2010, 363: 2081-2084. PMID: 21083379, DOI: 10.1056/nejmp1011042.Peer-Reviewed Original Research
2006
Trends in Acute Myocardial Infarction in 4 US States Between 1992 and 2001
Masoudi FA, Foody JM, Havranek EP, Wang Y, Radford MJ, Allman RM, Gold J, Wiblin RT, Krumholz HM. Trends in Acute Myocardial Infarction in 4 US States Between 1992 and 2001. Circulation 2006, 114: 2806-2814. PMID: 17145994, DOI: 10.1161/circulationaha.106.611707.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionAngiotensin-converting enzyme inhibitorEnzyme inhibitorsPrimary discharge diagnosisHealth system perspectiveQuality of careMore comorbiditiesClinical characteristicsDischarge diagnosisMyocardial infarctionAMI careMedicare patientsMultivariable modelTreatment criteriaMedicare populationTreatment ratesAspirinHealth impactsMortalityCarePresent studyOutcomesIndicator definitionsDiverse populationsInhibitorsHydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction
Foody JM, Rathore SS, Galusha D, Masoudi FA, Havranek EP, Radford MJ, Krumholz HM. Hydroxymethylglutaryl‐CoA Reductase Inhibitors in Older Persons with Acute Myocardial Infarction: Evidence for an Age–Statin Interaction. Journal Of The American Geriatrics Society 2006, 54: 421-430. PMID: 16551308, PMCID: PMC2797316, DOI: 10.1111/j.1532-5415.2005.00635.x.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAged, 80 and overAtorvastatinCholesterol, LDLDrug PrescriptionsFatty Acids, MonounsaturatedFemaleFluvastatinFollow-Up StudiesHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesLovastatinMaleMyocardial InfarctionOdds RatioPravastatinPyridinesPyrrolesRetrospective StudiesSurvival RateTreatment OutcomeConceptsAcute myocardial infarctionHydroxymethylglutaryl-CoA reductase inhibitorsStatin therapyMyocardial infarctionLower mortalityOlder personsReductase inhibitorsPrincipal discharge diagnosisAcute care hospitalsCause mortalityEligible patientsOlder patientsYounger patientsCare hospitalDischarge prescriptionsPrimary outcomeDischarge diagnosisHospital characteristicsEfficacy dataMedicare patientsMultivariable modelObservational studyPatientsStatinsDischarge statins
2005
Aspirin Use in Older Patients With Heart Failure and Coronary Artery Disease National Prescription Patterns and Relationship With Outcomes
Masoudi FA, Wolfe P, Havranek EP, Rathore SS, Foody JM, Krumholz HM. Aspirin Use in Older Patients With Heart Failure and Coronary Artery Disease National Prescription Patterns and Relationship With Outcomes. Journal Of The American College Of Cardiology 2005, 46: 955-962. PMID: 16168275, DOI: 10.1016/j.jacc.2004.07.062.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAspirinCoronary Artery DiseaseDrug PrescriptionsFemaleHeart FailureHumansMaleTreatment OutcomeConceptsCoronary artery diseaseHeart failureAspirin prescriptionAspirin useRenal insufficiencyLower riskLower unadjusted ratesNational prescription patternsUse of aspirinClustering of patientsEvidence of harmCause readmissionCoronary eventsOlder patientsPrescription patternsSecondary preventionArtery diseaseACE inhibitorsMultivariable analysisUnadjusted ratesHospital characteristicsTreatment benefitMedicare beneficiariesAspirinPatientsAdoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001
Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM. Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001. Circulation 2005, 112: 39-47. PMID: 15983243, DOI: 10.1161/circulationaha.104.527549.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCohort StudiesCreatinineDiureticsDrug PrescriptionsFemaleFollow-Up StudiesHeart FailureHumansMaleMineralocorticoid Receptor AntagonistsPatient SelectionPotassiumRandomized Controlled Trials as TopicRisk AssessmentSpironolactoneUnited StatesVentricular Dysfunction, LeftConceptsRandomized Aldactone Evaluation StudyPublication of RALESVentricular systolic dysfunctionHeart failureEnrollment criteriaSpironolactone prescriptionSpironolactone therapySystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionPatients meeting enrollment criteriaSerial cross-sectional samplesSevere renal dysfunctionSerum creatinine valuesAldactone Evaluation StudyMultivariable logistic regressionSerum potassium valuesSkilled nursing facilitiesNoncardiovascular comorbiditiesSpironolactone useRenal dysfunctionAdverse eventsHospital dischargeAppropriate patientsMultivariable analysis
2004
National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National Patterns of Use and Effectiveness of Angiotensin-Converting Enzyme Inhibitors in Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation 2004, 110: 724-731. PMID: 15289383, DOI: 10.1161/01.cir.0000138934.28340.ed.Peer-Reviewed Original ResearchConceptsACE inhibitor prescriptionAngiotensin receptor blockersVentricular systolic dysfunctionHeart failureACE inhibitorsInhibitor prescriptionSystolic dysfunctionOlder patientsLeft ventricular systolic dysfunctionAngiotensin converting enzyme (ACE) inhibitorsSerum creatinine levelsACE inhibitor useCreatinine levelsHospital factorsInhibitor useReceptor blockersSerum creatininePatient genderClinical trialsTherapeutic substitutionLower riskEnzyme inhibitorsLower mortalityPatientsSecondary analysisAssociation Between Functional Status and Use and Effectiveness of Beta‐Blocker Prophylaxis in Elderly Survivors of Acute Myocardial Infarction
Vitagliano G, Curtis JP, Concato J, Feinstein AR, Radford MJ, Krumholz HM. Association Between Functional Status and Use and Effectiveness of Beta‐Blocker Prophylaxis in Elderly Survivors of Acute Myocardial Infarction. Journal Of The American Geriatrics Society 2004, 52: 495-501. PMID: 15066062, DOI: 10.1111/j.1532-5415.2004.52153.x.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAcute DiseaseAdrenergic beta-AntagonistsAge FactorsAgedAged, 80 and overCross-Sectional StudiesDrug PrescriptionsDrug UtilizationFemaleGeriatric AssessmentHumansLogistic ModelsMaleMultivariate AnalysisMyocardial InfarctionPatient DischargePatient SelectionPractice Patterns, Physicians'Proportional Hazards ModelsRetrospective StudiesSurvival AnalysisTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionHospital dischargeFunctional impairmentElderly patientsMyocardial infarctionAcute myocardial infarction survivorsBeta-blocker prescriptionBeta-blocker prophylaxisBeta-blocker treatmentRetrospective cohort studySimilar survival benefitMain outcome measuresMyocardial infarction survivorsAcute care hospitalsEligible patientsCohort studySurvival benefitCare hospitalFunctional statusNational cohortInfarction survivorsOutcome measuresElderly survivorsPatientsCognitive impairment
1997
Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age
Krumholz H, Vaccarino V, Ellerbeck E, Kiefe C, Hennen J, Kresowik T, Gold J, Jencks S, Radford M. Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age. The American Journal Of Cardiology 1997, 79: 581-586. PMID: 9068512, DOI: 10.1016/s0002-9149(96)00819-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlabamaAngiotensin-Converting Enzyme InhibitorsConnecticutContraindicationsControlled Clinical Trials as TopicDecision MakingDiabetes ComplicationsDiureticsDrug PrescriptionsDrug UtilizationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansIowaMaleMedicaidMultivariate AnalysisMyocardial InfarctionPatient DischargeRetrospective StudiesStroke VolumeTachycardia, VentricularUnited StatesVentricular Function, LeftWisconsinConceptsAcute myocardial infarctionACE inhibitorsMyocardial infarctionDischarge medicationsVentricular functionEnzyme inhibitorsLeft ventricular ejection fractionAngiotensin-converting enzyme inhibitorAngiotensin converting enzyme (ACE) inhibitorsVentricular Enlargement (SAVE) trialCongestive heart failureVentricular ejection fractionYears of ageEligible patientsPatient characteristicsAppropriate patientsDiabetes mellitusEjection fractionHeart failureLoop diureticsMultivariable analysisVentricular tachycardiaIdeal patientObservational studyPatients